Continuing to invest in its immuno-oncology portfolio, Gilead Sciences has agreed to expand its collaboration with Tango Therapeutics to increase the number of targets from five to 15. The deal builds on a 2018 agreement between the two companies focused on the discovery, development and commercialisation of immuno-oncology therapies derived from Tango’s functional genomics-based discovery platform. By expanding the number of targets with the Tango deal, it signals that Gilead is satisfied with the progress of the original collaboration and sees significant potential in the field of synthetic lethality, an area that is gaining traction amongst big pharma.